CLINICAL ROLE -
Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.
Valoctocogene Roxaparvovec-Rvox Demonstrates Long-Term Safety and Efficacy in 4-Year Clinical Trial Data
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
Conditioning Regimens Followed by alloSCT Demonstrates Long-Term Survival With R/R AML
Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia
Inebilizumab-Cdon Reduces Risk of IgG4-Related Disease Flares By 87% In Adult Patients
Asciminib Shows Superior Efficacy, Favorable Safety in Patients With Newly Diagnosed Chronic Myeloid Leukemia